Form D · Biotechnology
DermBiont, Inc.
Boston, MA · CIK 0001779253
Offering snapshot reported Nov 13, 2024 · SEC filing
- Reported sold
- $32.7M Offering amount: $45.3M
- Investors reported
- 72 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 4, 2023 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$19,397,474 → $32,697,081
- Reported investors81 → 72
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 13, 2024 | Amendment | $32,697,081 | $13,299,607vs Oct 19, 2023 | 72 | SEC filing |
| Oct 19, 2023 | Amendment | $19,397,474 | $11,308,353vs Oct 19, 2023 | 81 | SEC filing |
| Oct 19, 2023 | Initial | $8,089,121 | No comparison | 10 | SEC filing |
| Mar 21, 2023 | Initial | $4,693,564 | No comparison | 69 | SEC filing |
| Sep 19, 2022 | Initial | $2,514,010 | No comparison | 11 | SEC filing |
| Jan 14, 2022 | Initial | $830,267 | No comparison | 10 | SEC filing |
| Dec 29, 2021 | Initial | $28,845,632 | No comparison | 42 | SEC filing |
| Aug 19, 2021 | Initial | $19,171,591 | No comparison | Not reported | SEC filing |
| Feb 24, 2021 | Initial | $6,550,582 | No comparison | 19 | SEC filing |
| Oct 30, 2020 | Initial | $7,200,004 | No comparison | 19 | SEC filing |
| Mar 4, 2020 | Initial | $2,871,893 | No comparison | 14 | SEC filing |
| Jun 11, 2019 | Initial | $8,789,465 | No comparison | 42 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-495206
$21,388,728.28 new money; up to $12,615,602.32 in pay-to-play second closing; $2,052,390.94 conversion of SAFEs; $9,255,961.88 conversion of notes
Source: Form D, filed Nov 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Basta | Director |
| Karl R. Beutner | Director, Executive |
| Robert Brucker | Executive |
| Max Dawson | Executive |
| Nichola Eliovits | Director, Executive |
| Jennifer Lee | Director |
| Wilder Ramsey | Director |
| Ramsey Wilder | Director |
| Daniel Yadegar | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
75 Kneeland St Fl 14
Boston, MA, 02111
Boston, MA, 02111